Now showing items 1-2 of 2

    • Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer 

      D'Andrea, David; Black, Peter C.; Zargar, Homayoun; Zargar-Shoshtari, Kamran; Zehetmayer, Sonja; Fairey, Adrian S.; Mertens, Laura S.; Dinney, Colin P.; Mir, Maria C.; Krabbe, Laura Maria; Cookson, Michael S.; Jacobsen, Niels Erik; Montgomery, Jeffrey S.; Vasdev, Nikhil; Yu, Evan Y.; Xylinas, Evanguelos; Campain, Nicholas J.; Kassouf, Wassim; Dall'Era, Marc A.; Seah, Jo An; Ercole, Cesar E.; Horenblas, Simon; Sridhar, Srikala S.; McGrath, John S.; Aning, Jonathan; Wright, Jonathan L.; Thorpe, Andrew C.; Morgan, Todd M.; Holzbeierlein, Jeffrey M.; Bivalacqua, Trinity J.; North, Scott; Barocas, Daniel A.; Lotan, Yair; Grivas, Petros; Stephenson, Andrew J.; Shah, Jay B.; van Rhijn, Bas W.; Daneshmand, Siamak; Spiess, Philippe E.; Shariat, Shahrokh F. (2020-02-11)
      Objective: To assess the effect of patient's sex on response to neoadjuvant chemotherapy (NAC) in patients with clinically nonmetastatic muscle-invasive bladder cancer (MIBC). Methods: Complete pathologic response, defined ...
    • Multicenter Evaluation of Neoadjuvant and Induction Gemcitabine-Carboplatin versus Gemcitabine-Cisplatin Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer 

      Einerhand, Sarah MH; Black, Anna J; Zargar, Homayoun; Fairey, Adrian S.; Dinney, Colin P; Mir, Maria C; Krabbe, Laura-Maria; Cookson, Michael S.; Jacobson, Niels-Erik; Montgomery, Jeffrey S; Vasdev, Nikhil; Yu, Evan Y; Xylinas, Evanguelos; Kassouf, Wassim; Dall’Era, Marc A.; Sridhar, Srikala S.; McGrath, Jonathan S; Aning, Jonathan; Shariat, Shahrokh F; Wright, Jonathan L.; Thorpe, Andrew C.; Morgan, Todd M; Holzbeierlein, Jeff M.; Bivalacqua, Trinity J; North, Scott; Barocas, Daniel A.; Lotan, Yair; Grivas, Petros; Garcia, Jorge A; Stephenson, Andrew J; Shah, Jay B; Daneshmand, Simak; Zargar-Shoshtari, Kamran; Spiess, P. E.; van Rhijn, Bas W; Black, Peter C.; Mertens, L. S. (2022-09-28)
      PurposeCisplatin-based chemotherapy followed by radical cystectomy (RC) is recommended in patients with muscle-invasive bladder cancer (MIBC). However, up to 50% of patients are cisplatin-ineligible. The aim of this study ...